7 research outputs found
A novel potent Fas agonist for selective depletion of tumor cells in hematopoietic transplants
There remains a clear need for effective tumor cell purging in autologous stem cell transplantation (ASCT) where residual malignant cells within the autograft contribute to disease relapse. Here we propose the use of a novel Fas agonist with potent pro-apoptotic activity, termed MegaFasL, as an effective ex-vivo purging agent. MegaFasL selectively kills hematological cancer cells from lymphomas and leukemias and prevents tumor development at concentrations that do not reduce the functional capacity of human hematopoietic stem/progenitor cells both in in vitro and in in vivo transplantation models. These findings highlight the potential use of MegaFasL as an ex-vivo purging agent in ASCT
Art and science of photodynamic therapy
10.1111/j.1440-1681.2006.04406.xClinical and Experimental Pharmacology and Physiology335-6551-55